Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb Company, today announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitman’s lab at the Harvard School of Dental Medicine.
- April 01, 2015
Paris (France), 1 April 2015 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has signed a multi-year research alliance agreement with Harvard University in Cambridge, Mass.
- March 04, 2015
NEWTON, Mass.--(BUSINESS WIRE)--Macrolide Pharmaceuticals, a new company with groundbreaking technology to develop novel antibiotics, completed a Series A financing of $22 million led by Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing follows a worldwide license agreement between Harvard's Office of Technology Development and the company, providing exclusive rights to the technology.
- November 22, 2013
On November 20 and 21, OTD once again brought together industry experts and Harvard investigators together for an intensive look at the drug development process.